Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

796
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
796
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

922
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
922
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

699
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
699
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

639
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
639

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines for a therapeutic alliance between families and staff: a report of the SIOP Working Committee on Psychosocial Issues in Pediatric Oncology.

Medical and pediatric oncology·1998
Same author

SIOP Working Committee on psychosocial issues in pediatric oncology: guidelines for communication of the diagnosis.

Medical and pediatric oncology·1997
Same author

Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study.

Cancer·1996
Same author

A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma.

Cancer·1993
Same author

Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988.

Cancer·1992
Same author

Rhabdomyosarcoma. A new classification scheme related to prognosis.

Archives of pathology & laboratory medicine·1992
Same journal

Rhabdomyolysis associated with high-dose cytarabine.

Cancer treatment reports·1987
Same journal

Acute laryngeal edema after single-dose irradiation and doxorubicin.

Cancer treatment reports·1987
Same journal

Timing may be a critical factor in drug therapy.

Cancer treatment reports·1987
Same journal

Prednimustine in advanced malignant melanoma: a phase II study.

Cancer treatment reports·1987
Same journal

Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

Cancer treatment reports·1987
Same journal

Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

Cancer treatment reports·1987
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K

Adjuvant chemotherapy for osteogenic sarcoma.

E Etcubanas, J R Wilbur

    Cancer Treatment Reports
    |February 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    This study investigated adjuvant chemotherapy for nonmetastatic osteosarcoma. While some patients achieved disease-free survival, the treatment did not significantly prevent the development of distant metastases.

    More Related Videos

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
    07:55

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

    Published on: April 11, 2018

    15.2K
    Sequential In vivo Imaging of Osteogenic Stem/Progenitor Cells During Fracture Repair
    10:30

    Sequential In vivo Imaging of Osteogenic Stem/Progenitor Cells During Fracture Repair

    Published on: May 23, 2014

    11.1K

    Related Experiment Videos

    Last Updated: Feb 11, 2026

    A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
    07:15

    A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

    Published on: July 28, 2020

    10.3K
    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
    07:55

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

    Published on: April 11, 2018

    15.2K
    Sequential In vivo Imaging of Osteogenic Stem/Progenitor Cells During Fracture Repair
    10:30

    Sequential In vivo Imaging of Osteogenic Stem/Progenitor Cells During Fracture Repair

    Published on: May 23, 2014

    11.1K

    Area of Science:

    • Oncology
    • Pediatric Oncology
    • Chemotherapy

    Background:

    • Osteosarcoma is a rare bone cancer primarily affecting children and young adults.
    • Adjuvant chemotherapy is a standard treatment to reduce the risk of cancer recurrence.
    • Effective adjuvant chemotherapy regimens are crucial for improving osteosarcoma patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy of a sequential combination chemotherapy regimen in preventing metastasis in nonmetastatic osteosarcoma patients.
    • To assess the disease-free survival and overall survival rates in patients receiving adjuvant chemotherapy.
    • To determine if the studied chemotherapy protocol significantly impacts the development of overt metastases.

    Main Methods:

    • A sequential combination chemotherapy regimen was administered to 29 evaluable patients with nonmetastatic osteosarcoma.
    • The regimen included high-dose methotrexate with citrovorum factor rescue, vincristine, adriamycin, and cyclophosphamide.
    • Patient outcomes, including disease-free survival and overall survival, were monitored.

    Main Results:

    • Of 29 patients, 14 (48%) remained disease-free for 8-48 months, with a median disease-free survival of 21 months.
    • Projected 4-year disease-free survival was 13%, and projected 4-year overall survival was 57%.
    • Adjuvant chemotherapy did not appear to significantly prevent the development of overt metastases, with four patients experiencing delayed metastasis onset.

    Conclusions:

    • The studied sequential combination chemotherapy regimen showed limited success in preventing distant metastases in nonmetastatic osteosarcoma.
    • Delayed onset of metastasis was observed in a subset of patients, suggesting the need for further investigation into treatment strategies.
    • Current adjuvant chemotherapy protocols may require optimization to improve long-term disease control and survival in osteosarcoma.